Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

BACKGROUND: Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Paule, Ines, Sassi, Hind, Habibi, Anoosha, Pham, Kim PD, Bachir, Dora, Galactéros, Frédéric, Girard, Pascal, Hulin, Anne, Tod, Michel
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3118100/
https://ncbi.nlm.nih.gov/pubmed/21619673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-6-30
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados